Literature DB >> 15832415

Effects of pharmacological serum from normal and liver fibrotic rats on HSCs.

Xi-Xian Yao1, Tao Lv.   

Abstract

AIM: To make drug sera of Salvia miltiorrhiza and Yigankang, both of which are Chinese herbs that activate bleeding and eliminate stasis, in normal rats and those with liver fibrosis, respectively. To investigate and compare the effects of the two different drug sera on the proliferation and activation of hepatic stellate cells (HSCs).
METHODS: Some rats were induced with liver fibrosis: 40% carbon tetrachloride (CCl4) subcutaneous injection, twice a week for 9 wk. Salvia miltiorrhiza, Yigankang, colchicines and normal saline were administered into the stomachs of normal rats and those with liver fibrosis. Drug sera were extracted 5 d later. HSCs in vitro were cultivated in different drug sera for 24 h. The rates of proliferation and expression of alpha-smooth muscle actin (alpha-SMA) were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and immunocytochemistry stain, respectively.
RESULTS: The drug sera from normal and liver fibrotic rats could be used to cultivate HSCs and to observe the effects of the corresponding components of herbs on HSCs. Salvia miltiorrhiza and Yigankang had better inhibitory effects on HSCs than colchicines (MTT: normal drug serum: Salvia miltiorrhiza 0.42+/-0.08, Yigankang 0.32+/-0.10 vs colchicines 0.45+/-0.12 pathological drug serum: Salvia miltiorrhiza 0.33+/-0.02, Yigankang 0.26+/-0.01 vs colchicines 0.41+/-0.09. P<0.05). The drug sera of Salvia miltiorrhiza, Yigankang from liver fibrotic rats had a stronger inhibitory effect than the same ones from normal rats (MTT: Salvia miltiorrhiza: normal drug serum 0.42+/-0.08 vs pathological drug serum 0.33+/-0.02. Yigankang: normal drug serum 0.32+/-0.10 vs pathological drug serum 0.26+/-0.01. P<0.05).
CONCLUSION: Salvia miltiorrhiza and Yigankang could inhibit the expression of alpha-SMA and the proliferation of HSCs. The drug sera from normal and liver fibrotic rats had different effects on HSCs, probably due to different metabolic processes, effective components and different quantities of drug contents in drug sera from rats with different states of liver.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832415      PMCID: PMC4305632          DOI: 10.3748/wjg.v11.i16.2444

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

Review 1.  Hepatic stellate cells: a target for the treatment of liver fibrosis.

Authors:  J Wu; M A Zern
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

2.  [Effect of anti-fibrosis compound contained serum on procollagen Type I and IV, matrix metalloproteinase and its tissue inhibitor-1 gene expression in HSC-LI90 cell line].

Authors:  Gang Zhao; Ling-tai Wang; Jian-jie Chen
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2004-01

Review 3.  Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension.

Authors:  J Reichen
Journal:  Hepatology       Date:  1990-06       Impact factor: 17.425

4.  [Effect of concentrated xuefu zhuyu pill on proliferation of vascular smooth muscle cells in experimental atheriosclerosis rabbits observed by serologic pharmacological test].

Authors:  Q H Zhang; B Zhong; K J Chen
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  1996-03

Review 5.  Antifibrogenic therapies in chronic HCV infection.

Authors:  I Shimizu
Journal:  Curr Drug Targets Infect Disord       Date:  2001-08

Review 6.  Impact of oestrogens on the progression of liver disease.

Authors:  Ichiro Shimizu
Journal:  Liver Int       Date:  2003-02       Impact factor: 5.828

7.  A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease.

Authors:  Marcus Mühlbauer; Anja K Bosserhoff; Arndt Hartmann; Wolfgang E Thasler; Thomas S Weiss; Hans Herfarth; Guntram Lock; Jürgen Schölmerich; Claus Hellerbrand
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

8.  Inhibitory effects of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells.

Authors:  K Kayano; I Sakaida; K Uchida; K Okita
Journal:  J Hepatol       Date:  1998-10       Impact factor: 25.083

9.  [Inhibition of the activation and collagen production of cultured rat hepatic stellate cells by antisense oligonucleotides against transforming growth factor-beta 1 is enhanced by cationic liposome delivery].

Authors:  X Liu; Z Zhang; L Yang; D Chen; Y Wang
Journal:  Hua Xi Yi Ke Da Xue Xue Bao       Date:  2000-06

10.  Effects of hepatic stimulator substance, herbal medicine, selenium/vitamin E, and ciprofloxacin on cirrhosis in the rat.

Authors:  M Zhang; G Song; G Y Minuk
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

View more
  3 in total

1.  Comparison of protocatechuic aldchyde in Radix Salvia miltiorrhiza and corresponding pharmacological sera from normal and fibrotic rats by high performance liquid chromatography.

Authors:  Tao Lv; Xi-Xian Yao
Journal:  World J Gastroenterol       Date:  2006-04-14       Impact factor: 5.742

2.  Interleukin-1 beta up-regulates tissue inhibitor of matrix metalloproteinase-1 mRNA and phosphorylation of c-jun N-terminal kinase and p38 in hepatic stellate cells.

Authors:  Ya-Ping Zhang; Xi-Xian Yao; Xia Zhao
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

3.  Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis.

Authors:  Florent Duval; Jorge E Moreno-Cuevas; María Teresa González-Garza; Carlos Rodríguez-Montalvo; Delia Elva Cruz-Vega
Journal:  Chin Med       Date:  2014-12-24       Impact factor: 5.455

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.